Research & Literature

Glucocorticoid-Responsive Cold Agglutinin Disease in a Patient with Rheumatoid Arthritis.

Honne K, Nagashima T, Iwamoto M, et al.

Case reports in rheumatology 2015; (2015()):823563 doi:10.1155/2015/823563.

Cold agglutinin disease.

Berentsen S

Hematology. American Society of Hematology. Education Program 2016; (2016(1)):226-231 doi:10.1182/asheducation-2016.1.226.

Bendamustine plus rituximab for chronic cold agglutinin disease: results of a Nordic prospective multicenter trial.

Berentsen S, Randen U, Oksman M, et al.

Blood 2017; (130(4)):537-541 doi:10.1182/blood-2017-04-778175.

How I manage patients with cold agglutinin disease.

Berentsen S

British journal of haematology 2018; (181(3)):320-330 doi:10.1111/bjh.15109.

A Rare Non-Hemolytic Case of Idiopathic Cold Agglutinin Disease.

Erkus E, Kocak MZ, Aktas G, et al.

Clinical laboratory 2018; (64(6)):1075-1078 doi:10.7754/Clin.Lab.2018.180114.

Unusual underlying disorder for pulmonary embolism: Cold agglutinin disease.

Onishi S, Ichiba T, Miyoshi N, et al.

Journal of cardiology cases 2017; (15(2)):43-45 doi:10.1016/j.jccase.2016.10.005.

Inhibition of complement C1s improves severe hemolytic anemia in cold agglutinin disease: a first-in-human trial.

Jäger U, D'Sa S, Schörgenhofer C, et al.

Blood 2019; (133(9)):893-901 doi:10.1182/blood-2018-06-856930.

Effect of a C1s Inhibitor on the Efficacy of Anti-Capsular Antibodies against Neisseria meningitidis and Streptococcus pneumoniae.

Lewis LA, Panicker S, DeOliveira RB, et al.

ImmunoHorizons 2019; (3(11)):519-530 doi:10.4049/immunohorizons.1900031.

Inhibition of complement C1s in patients with cold agglutinin disease: lessons learned from a named patient program.

Gelbenegger G, Schoergenhofer C, Derhaschnig U, et al.

Blood advances 2020; (4(6)):997-1005 doi:10.1182/bloodadvances.2019001321.

New Insights in the Pathogenesis and Therapy of Cold Agglutinin-Mediated Autoimmune Hemolytic Anemia.

Berentsen S

Frontiers in immunology 2020; (11()):590 doi:10.3389/fimmu.2020.00590.

Cold agglutinin disease revisited: a multinational, observational study of 232 patients.

Berentsen S, Barcellini W, D'Sa S, et al.

Blood 2020; (136(4)):480-488 doi:10.1182/blood.2020005674.

Increasing Incidence and Prevalence of Acquired Hemolytic Anemias in Denmark, 1980-2016.

Hansen DL, Möller S, Andersen K, et al.

Clinical epidemiology 2020; (12()):497-508 doi:10.2147/CLEP.S250250.

Increased risk of thrombotic events in cold agglutinin disease: A 10-year retrospective analysis.

Broome CM, Cunningham JM, Mullins M, et al.

Research and practice in thrombosis and haemostasis 2020; (4(4)):628-635 doi:10.1002/rth2.12333.

Demographic characteristics, thromboembolism risk, and treatment patterns for patients with cold agglutinin disease in Japan.

Kamesaki T, Nishimura JI, Wada H, et al.

International journal of hematology 2020; (112(3)):307-315 doi:10.1007/s12185-020-02899-6.

How I treat cold agglutinin disease.

Berentsen S

Blood 2021; (137(10)):1295-1303 doi:10.1182/blood.2019003809.

Multifocal thrombosis with peripheral gangrene in a young boy: Mycoplasma infection triggered cold agglutinin disease.

Sudhakar M, Mohandoss V, Chaudhary H, et al.

Immunobiology 2021; (226(3)):152075 doi:10.1016/j.imbio.2021.152075.

Cold agglutinin-induced hemolytic anemia during room temperature fluid resuscitation: a case report.

Kawai Y, Deguchi M, Mizouchi N, et al.

Journal of medical case reports 2021; (15(1)):169 doi:10.1186/s13256-021-02784-8.

Cold Agglutinin Disease.

Gabbard AP, Booth GS

Clinical hematology international 2020; (2(3)):95-100 doi:10.2991/chi.k.200706.001.

Complement-mediated hemolysis persists year round in patients with cold agglutinin disease.

Röth A, Fryzek J, Jiang X, et al.

Transfusion 2022; (62(1)):51-59 doi:10.1111/trf.16745.

Complement Mediated Hemolytic Anemias in the COVID-19 Era: Case Series and Review of the Literature.

Fattizzo B, Pasquale R, Bellani V, et al.

Frontiers in immunology 2021; (12()):791429 doi:10.3389/fimmu.2021.791429.

Exacerbation of Secondary Cold Agglutinin Syndrome in the Setting of SARS-CoV-2.

Bhagat YV, Hussien S, Queenan H, Michael MB

Cureus 2021; (13(11)):e19387 doi:10.7759/cureus.19387.

A Rare Case of Severe Hemolytic Anemia and Pulmonary Embolism Secondary to Mycoplasma pneumoniae Infection.

Kumaravel Kanagavelu AS, Nagumantry SK, Sagi SV, Oyibo SO

Journal of medical cases 2022; (13(3)):119-124 doi:10.14740/jmc3866.

Sutimlimab: First Approval.

Dhillon S

Drugs 2022; (82(7)):817-823 doi:10.1007/s40265-022-01711-5.

Sutimlimab in patients with cold agglutinin disease: results of the randomized placebo-controlled phase 3 CADENZA trial.

Röth A, Berentsen S, Barcellini W, et al.

Blood 2022; (140(9)):980-991 doi:10.1182/blood.2021014955.

The Burden of Cold Agglutinin Disease on Patients' Daily Life: Web-Based Cross-sectional Survey of 50 American Patients.

Joly F, Schmitt LA, Watson PAM, et al.

JMIR formative research 2022; (6(7)):e34248 doi:10.2196/34248.

Development of the Cold Agglutinin Disease Symptoms and Impact Questionnaire (CAD-SIQ).

Joly F, DasMahapatra P, DiBenedetti DB, et al.

European journal of haematology 2023; (111(2)):211-219 doi:10.1111/ejh.13984.

Sutimlimab Pharmacokinetics and Pharmacodynamics in Patients with Cold Agglutinin Disease.

Frank T, Kovar A, Strougo A, et al.

The Journal of pharmacology and experimental therapeutics 2023; (386(2)):143-155 doi:10.1124/jpet.122.001511.

Clinical and laboratory characteristics of patients with cold agglutinin disease: A retrospective analysis at a tertiary medical center.

Mehrotra H, Otrock ZK

Asian journal of transfusion science 2023; (17(2)):229-233 doi:10.4103/ajts.ajts_65_23.

IgA plasma cell myeloma presenting as cold agglutinin-induced haemolytic transfusion reaction.

Mehdipour Dalivand M, Woddor N, Makuria A, et al.

BMJ case reports 2024; (17(2)) doi:10.1136/bcr-2022-251638.

When you think you should transfuse…don't!

Gammon RR, Alvarez H, Masias C, et al.

Laboratory medicine 2024; (55(5)):663-666 doi:10.1093/labmed/lmae024.

Autoimmune Hemolytic Anemias: Classifications, Pathophysiology, Diagnoses and Management.

Loriamini M, Cserti-Gazdewich C, Branch DR

International journal of molecular sciences 2024; (25(8)) doi:10.3390/ijms25084296.

The evolving management algorithm for the patient with newly diagnosed cold agglutinin disease.

Barcellini W, Fattizzo B

Expert review of hematology 2024; (17(7)):287-294 doi:10.1080/17474086.2024.2366540.

Cold-antibody Autoimmune Hemolytic Anemia: its Association with Neoplastic Disease and Impact on Therapy.

Berentsen S

Current oncology reports 2024; (26(9)):1085-1096 doi:10.1007/s11912-024-01569-8.

[Cold agglutinin disease: pathology, diagnosis, and treatment].

Wada H

[Rinsho ketsueki] The Japanese journal of clinical hematology 2024; (65(6)):521-528 doi:10.11406/rinketsu.65.521.

Long-term efficacy and safety of continued complement C1s inhibition with sutimlimab in cold agglutinin disease: CADENZA study Part B.

Röth A, Berentsen S, Barcellini W, et al.

EClinicalMedicine 2024; (74()):102733 doi:10.1016/j.eclinm.2024.102733.

[83-year-old with angina pectoris, hemoglobinuria and icterus].

Dickmann F, Janssens U

Deutsche medizinische Wochenschrift (1946) 2025; (150(4)):163-166 doi:10.1055/a-2432-3518.

Ambulatory total knee arthroplasty in a patient with cold agglutinin disease.

Bansal S

Canadian journal of anaesthesia = Journal canadien d'anesthesie 2025; (72(6)):1015-1020 doi:10.1007/s12630-025-02961-z.

Prevalence and incidence of primary autoimmune hemolytic anemia and cold agglutinin disease in the United States, 2016-2023.

Bozzi S, Umarje S, Hawaldar K, et al.

PloS one 2025; (20(6)):e0323843 doi:10.1371/journal.pone.0323843.

A case of autoimmune hemolytic anemia with cold agglutinin disease post-operation for recurrent ovarian cancer.

Sugimoto A, Yamada H, Tasaki K, et al.

International cancer conference journal 2025; (14(3)):235-240 doi:10.1007/s13691-025-00758-x.

[Cold agglutinin disease (CAD)].

Röth A, Borchert K, Dorn C, et al.

Innere Medizin (Heidelberg, Germany) 2025; (66(9)):986-996 doi:10.1007/s00108-025-01926-0.

Cold Agglutinin Syndrome as the Initial Presentation of Acute Myeloid Leukemia: A Case Report.

Sadeghi MV, Vosough Z, Jahansouz D

Clinical case reports 2025; (13(10)):e71061 doi:10.1002/ccr3.71061.

Refractory cold autoimmune hemolytic anemia as initial presentation of gastric B cell lymphoma: a case report.

Fernando G, Samarasingha SAPN, Karunatilake H, et al.

Journal of medical case reports 2025; (19(1)):487 doi:10.1186/s13256-025-05519-1.

Diagnosis and management of cold agglutinin disease.

Berentsen S

Hematology. American Society of Hematology. Education Program 2025; (2025(1)):295-304 doi:10.1182/hematology.2025000718.

Case Report: Refractory cold agglutinin disease with hypersplenism: efficacy of splenectomy in a patient treated with sutimlimab.

Sau A, Onofrillo D, Russo AC, et al.

Frontiers in immunology 2026; (17()):1770676 doi:10.3389/fimmu.2026.1770676.

Safety and Effectiveness of Sutimlimab in Cold Agglutinin Disease: A Real-World International Experience.

Fattizzo B, Sambruna E, Miyakawa Y, et al.

American journal of hematology 2026; (101(7)):1597-1604 doi:10.1002/ajh.70307.

Bone Marrow Pathology in Cold Agglutinin-Mediated Autoimmune Hemolytic Anemia: A Study of 56 Cases.

Becking AL, Bernelot Moens SJ, Kersten MJ, et al.

European journal of haematology 2026; (117(2)):384-395 doi:10.1111/ejh.70194.

Cold Agglutinin-Mediated Hemolytic Anemia Preceding the Diagnosis of Acute Myeloid Leukemia: A Case Report and Literature Review.

Tariq MA, Almahmood M, Mushtaq J, Incorvati J

Cureus 2026; (18(4)):e106577 doi:10.7759/cureus.106577.

Cold agglutinin disease: pathophysiology, diagnosis, and the evolving therapeutic landscape.

Choi DH

Blood research 2026; (61(1)).